Human Neuroscience

PHS 2021-2 Omnibus Solicitation of the NIH, CDC and FDA for Small Business Innovation Research Grant Applications (Parent SBIR [R43/R44] Clinical Trial Not Allowed)

The Notice of Special Interest (NOSI): Translation of BRAIN Initiative Technologies to the Marketplace, NOT-MH-21-125, encourages the translation of BRAIN Initiative-supported technologies from academic and other non-small business research sectors to the marketplace.

Addgene Launches Open Access Recombinant Antibody Resource for the Scientific Research Community

Addgene, the nonprofit biorepository, now produces and distributes ready-to-use recombinant antibodies. The inaugural collection of monoclonal antibodies is part of the Neuroscience AntiBody Open Resource (NABOR), a platform that provides open access to recombinant antibodies and affinity reagents for the neuroscience community. NABOR is supported by a grant from the National Institutes of Health’s Brain Research Through Advancing Innovative Neurotechnologies® (BRAIN) Initiative.

BRAIN Neuroethics Working Group (NEWG) Workshop on Continuing Trial Responsibilities

Participants of implanted neural device trials may have research-related care needs after the trial has ended. For example, these needs could include continued access to the device, device maintenance and support, explantation, and/or medical care resulting from participating in the research study. Discussions in the field suggest that investigators, grantee institutions, device manufacturers, funders and others involved in the trial have shared responsibilities to facilitate some of these needs.

Personalizing Deep Brain Stimulation for Treatment-Resistant Depression

Treatment-resistant depression (TRD) is diagnosed after an individual has tried several types of treatment for depression and their symptoms haven’t improved. The effectiveness of deep brain stimulation (DBS) as a treatment for disorders such as Parkinson’s disease has led researchers to investigate whether it could also work for psychiatric disorders such as TRD. However, depression varies significantly among individuals, and studies on DBS for TRD have also produced variable results. This points to a need to personalize DBS treatment for individuals with depression.

Labroots Neuroscience Virtual Conference

Labroots is excited to present the 10th Annual Neuroscience Virtual Conference, to be broadcasted live on March 10th, 2022.  This distinguished, online-only, event is free to attend and will once again bring together the neuroscience community to discuss and present the newest advances in understanding the human brain, neuropsychiatric disorders, and behavioral processes as it relates to the brain function. 

BRAIN Initiative: Development of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in Human and Non-Human Primate Brain (UG3/UH3 Clinical Trial Optional)

Reissue of RFA-MH-19-135 The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis and manipulation of complex circuits and provide insights into cellular interactions that underlie brain function. Critical advances in the treatment of brain disorders in human populations are hindered by our lack of ability to monitor and manipulate circuitry in safe, minimally-invasive ways.